281 related articles for article (PubMed ID: 32657172)
1. Anti-integrin therapy for retinovascular diseases.
Bhatwadekar AD; Kansara V; Luo Q; Ciulla T
Expert Opin Investig Drugs; 2020 Sep; 29(9):935-945. PubMed ID: 32657172
[TBL] [Abstract][Full Text] [Related]
2. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.
Shaw LT; Mackin A; Shah R; Jain S; Jain P; Nayak R; Hariprasad SM
Expert Opin Investig Drugs; 2020 Jun; 29(6):547-554. PubMed ID: 32349559
[TBL] [Abstract][Full Text] [Related]
3. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
6. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
7. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
8. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
9. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders.
Hu TT; Vanhove M; Porcu M; Van Hove I; Van Bergen T; Jonckx B; Barbeaux P; Vermassen E; Feyen JHM
Exp Eye Res; 2019 Mar; 180():43-52. PubMed ID: 30472075
[TBL] [Abstract][Full Text] [Related]
10. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmology Retina Enters Year 4: Some Comments on Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Schachat AP
Ophthalmol Retina; 2020 Jan; 4(1):1-2. PubMed ID: 31902470
[No Abstract] [Full Text] [Related]
12. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration.
Van Hove I; Hu TT; Beets K; Van Bergen T; Etienne I; Stitt AW; Vermassen E; Feyen JHM
Prog Retin Eye Res; 2021 Nov; 85():100966. PubMed ID: 33775825
[TBL] [Abstract][Full Text] [Related]
13. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease.
Campbell M; Doyle SL
Biochem Pharmacol; 2019 Jun; 164():321-325. PubMed ID: 31039332
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
[TBL] [Abstract][Full Text] [Related]
15. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
17. Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.
Bhatwadekar AD; Kansara VS; Ciulla TA
Expert Opin Investig Drugs; 2020 Mar; 29(3):237-244. PubMed ID: 31985300
[No Abstract] [Full Text] [Related]
18. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
Ou WC; Brown DM; Payne JF; Wykoff CC
Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
[TBL] [Abstract][Full Text] [Related]
19. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Hussain RM; Neiweem AE; Kansara V; Harris A; Ciulla TA
Expert Opin Investig Drugs; 2019 Oct; 28(10):861-869. PubMed ID: 31513439
[No Abstract] [Full Text] [Related]
20. Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration.
Mitsch C; Pemp B; Pollreisz A; Gleiss A; Karst S; Scholda C; Sacu S; Schmidt-Erfurth U
Acta Ophthalmol; 2020 May; 98(3):e301-e308. PubMed ID: 31654481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
